Download DNB 2019 June MEDICAL ONCOLOGY MEDICAL ONCOLOGY PAPER 1 Question Paper

FirstRanker.com

FINAL EXAM

JUNE 2019

--- Content provided by‍ FirstRanker.com ---

Time: 3 hours

MEDICAL ONCOLOGY

PAPER-I

Max. Marks: 100

Important Instructions:

--- Content provided by‌ FirstRanker.com ---

• Attempt all questions in order.
• Each question carries 10 marks.
• Read the question carefully and answer to the point neatly and legibly.
• Do not leave any blank pages between two answers.
• Indicate the question number correctly for the answer in the margin space.

--- Content provided by‍ FirstRanker.com ---

• Answer all the parts of a single question together.
• Start the answer to a question on a fresh page or leave adequate space between two answers.
• Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a) Next generation sequencing (NGS). (4+3+3)
   

   --- Content provided by‍ FirstRanker.com ---

   b) Passenger & Driver mutations.
   c) Allele-Specific polymerase chain reaction
2. What are the constituent cell types of the tumour microenvironment? (3+3+4)
3. Dynamics and co-evolution of the tumour microenvironment during the carcinogenesis. (4+4+2)
4. Mention therapies targeting hall marks of the cancer. (4+3+3)

--- Content provided by​ FirstRanker.com ---

5. Mechanisms of chemical carcinogenesis: (4+4+2)
6. a) Microbiota & carcinogenesis. (3+3+4)
   b) Cancers caused by EBV.
7. a) Mechanism of radiation induced cellular damage. (4+6)
   b) Proton beam therapy.
   

   --- Content provided by FirstRanker.com ---

   c) Radiosensitizers in cancer therapy.
8. a) Immune checkpoints in a cell and their inhibitors in cancer treatment.
   b) Adverse effects of immune check point inhibitors and their management.
   c) Talimogene laherparepvec (T-VEC).
9. a) Indications of Genetic counseling in hereditary cancer syndromes.
   

   --- Content provided by⁠ FirstRanker.com ---

   b) Components of Cancer Genetic counseling.
   c) Role of surgery in cancer prevention.
10. a) What is a tumour biomarker? (2+3+5)
    b) Potential uses of tumour biomarker tests.
    c) What are the criteria to incorporate a tumour biomarker test into clinical practice?

--- Content provided by​ FirstRanker.com ---

11. a) Anti HER-2 neu therapeutic agents in breast cancer. (4+3+3)
    b) Monitoring and management of cardiotoxicity of anti- HER 2 therapy.
    c) Differences between anthracyclin induced and anti- HER-2 agents induced cardiotoxicity.
12. a) What is a biosimilar? (2+4+4)
    b) Criteria used in biosimilar approval process.
    

    --- Content provided by⁠ FirstRanker.com ---

    c) Advantages & disadvantages of use of biosimilar.

FirstRanker.com

POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.